Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Aurinia Pharmaceuticals Inc (AUPH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/13/2025: AUPH (3-star) is a STRONG-BUY. BUY since 10 days. Profits (29.98%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $11.71
1 Year Target Price $11.71
| 3 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -4.77% | Avg. Invested days 34 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/13/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.49B USD | Price to earnings Ratio 26.33 | 1Y Target Price 11.71 |
Price to earnings Ratio 26.33 | 1Y Target Price 11.71 | ||
Volume (30-day avg) 6 | Beta 1.24 | 52 Weeks Range 5.51 - 12.10 | Updated Date 08/13/2025 |
52 Weeks Range 5.51 - 12.10 | Updated Date 08/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.43 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-07-31 | When - | Estimate 0.14 | Actual 0.16 |
Profitability
Profit Margin 23.31% | Operating Margin (TTM) 28.85% |
Management Effectiveness
Return on Assets (TTM) 7.69% | Return on Equity (TTM) 17.33% |
Valuation
Trailing PE 26.33 | Forward PE 17.86 | Enterprise Value 1256743460 | Price to Sales(TTM) 5.73 |
Enterprise Value 1256743460 | Price to Sales(TTM) 5.73 | ||
Enterprise Value to Revenue 4.83 | Enterprise Value to EBITDA 14.53 | Shares Outstanding 131630000 | Shares Floating 127581937 |
Shares Outstanding 131630000 | Shares Floating 127581937 | ||
Percent Insiders 9.31 | Percent Institutions 49.17 |
Upturn AI SWOT
Aurinia Pharmaceuticals Inc
Company Overview
History and Background
Aurinia Pharmaceuticals Inc. was founded in 2006. The company is focused on developing and commercializing therapies to treat autoimmune diseases, particularly lupus nephritis.
Core Business Areas
- Lupus Nephritis: The company's primary focus is on the development and commercialization of therapies for lupus nephritis (LN), a serious kidney disease caused by systemic lupus erythematosus (SLE).
Leadership and Structure
Peter Greenleaf is the President and Chief Executive Officer. The company has a typical corporate structure with departments such as research and development, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- LUPKYNIS (voclosporin): LUPKYNIS is Aurinia's only FDA-approved drug, used for the treatment of adult patients with active lupus nephritis in combination with a background immunosuppressive therapy regimen. As of the last market report, LUPKYNIS had approximately 25% market share in the LN treatment landscape. Competitors include Benlysta (belimumab) and cyclophosphamide. Revenue from this product accounts for almost the entirety of Aurinia's revenue.
Market Dynamics
Industry Overview
The market for lupus nephritis treatments is growing, driven by increasing awareness of the disease and the availability of new therapies. The industry is competitive, with several companies developing and marketing treatments for LN.
Positioning
Aurinia is positioned as a key player in the LN market, primarily based on the first oral therapy for the disease, LUPKYNIS. The company's competitive advantage lies in the efficacy and convenience of its treatment.
Total Addressable Market (TAM)
The total addressable market for lupus nephritis is estimated to be several billion dollars annually. Aurinia is positioned to capture a significant portion of this market with LUPKYNIS.
Upturn SWOT Analysis
Strengths
- FDA-approved therapy for lupus nephritis (LUPKYNIS)
- Strong intellectual property protection for LUPKYNIS
- Experienced management team
- Focused on a specific therapeutic area
Weaknesses
- Reliance on a single product (LUPKYNIS)
- Relatively small company size compared to competitors
- Market acceptance and uptake of LUPKYNIS
- Need to expand market share
Opportunities
- Expansion of LUPKYNIS label to include other indications
- Partnerships or collaborations with larger pharmaceutical companies
- Growth in the lupus nephritis market
- Geographic expansion of LUPKYNIS sales
Threats
- Competition from other lupus nephritis treatments
- Regulatory hurdles
- Pricing pressures
- Patent expiration of LUPKYNIS
Competitors and Market Share
Key Competitors
- GSK (GSK)
- Roche (RHHBY)
- Bristol-Myers Squibb (BMY)
Competitive Landscape
Aurinia's advantage lies in having the only oral therapy for lupus nephritis, but faces competition from established players like GSK and Roche with products like Benlysta and CellCept.
Growth Trajectory and Initiatives
Historical Growth: Aurinia's growth has been primarily driven by the commercialization of LUPKYNIS. Historical revenue data can be found in the company's financial reports.
Future Projections: Future growth projections are based on analyst estimates and the company's own guidance. These projections typically include revenue forecasts and EPS growth. These data are updated regularly on financial information sites.
Recent Initiatives: Recent initiatives include efforts to expand the market share of LUPKYNIS and to pursue potential label expansions.
Summary
Aurinia Pharmaceuticals is a pharmaceutical company focusing on lupus nephritis treatment with its drug LUPKYNIS. While LUPKYNIS is a strong asset and a first-in-class treatment with reasonable market share, the company's reliance on a single product poses a significant risk. Increasing competition, pricing pressures, and regulatory hurdles will impact future growth. Overall, Aurinia is moderately positioned within the LN market and must continue to strengthen its balance sheet.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Aurinia Pharmaceuticals Investor Relations
- SEC Filings
- Analyst Reports
- Company Press Releases
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share data are estimates and may vary. Financial data should be verified with the company's official reports.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aurinia Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Edmonton, AB, Canada | ||
IPO Launch date 1999-01-26 | President, CEO & Director Mr. Peter S. Greenleaf M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 130 | Website https://www.auriniapharma.com |
Full time employees 130 | Website https://www.auriniapharma.com | ||
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.